Daniel A.  Ninivaggi net worth and biography

Daniel Ninivaggi Biography and Net Worth

Director of Indivior

Daniel was appointed a Non-Executive Director in January 2025 and Chair of the Nomination Committee in March 2025.

Daniel is currently Chairman of the Board and Chair of the Finance Committee of Garrett Motion Inc. (NASDAQ:GTX), a Switzerland-based supplier of turbochargers and other products designed to improve energy efficiency and reduce emissions in vehicles and industrial equipment. He is also a member of the Management Executive Committee of Metalsa S.A (a non-public company). From August 2021 until March 2024, Daniel formerly served as the Chief Executive Officer and subsequently the Executive Chairman of Lordstown Motors Corp, an electric vehicle automaker.  Prior to that, he served as the President and Chief Executive Officer of Icahn Enterprises L.P. (IEP) (NASDAQ:IEP), the principal investment vehicle of Carl Icahn, between 2010 and 2014;  Co-Chief Executive Officer of Federal-Mogul Holdings Corp. (a public-company subsidiary of IEP now part of Apollo Global Management) from 2014 until 2017; and Chief Executive Officer of Icahn Automotive Group, LLC  and a Managing Director of IEP from  2017 until  2019. Prior to joining IEP, Daniel spent six years at Lear Corporation (NYSE:LEA), holding various senior executive positions.

Daniel has served as a director of numerous public and private companies, including Garrett Motion Inc., Lordstown Motors Corp., Hertz Global Holdings Inc., Navistar International Corporation, Icahn Enterprises G.P. Inc. (the general partner of Icahn Enterprises), CVR Energy Inc., XO Holdings, Tropicana Entertainment Inc., Motorola Mobility Holdings Inc., and CIT Group, Inc.

Daniel began his career at Skadden, Arps, Slate, Meagher & Flom LLP before joining Winston & Strawn LLP, where he became a partner specializing in mergers & acquisitions, financing transactions and corporate governance. He holds a Bachelor of Arts degree from Columbia University, an MBA from the University of Chicago Graduate School of Business, and a law degree (Juris Doctor) (with distinction) from Stanford University School of Law.

What is Daniel A. Ninivaggi's net worth?

The estimated net worth of Daniel A. Ninivaggi is at least $550.56 thousand as of January 5th, 2026. Ninivaggi owns 16,923 shares of Indivior stock worth more than $550,556 as of January 16th. This net worth estimate does not reflect any other investments that Ninivaggi may own. Learn More about Daniel A. Ninivaggi's net worth.

How do I contact Daniel A. Ninivaggi?

The corporate mailing address for Ninivaggi and other Indivior executives is 10710 Midlothian Turnpike, North Chesterfield, VA 23235, United States. Indivior can also be reached via phone at 804-379-1090 and via email at [email protected]. Learn More on Daniel A. Ninivaggi's contact information.

Has Daniel A. Ninivaggi been buying or selling shares of Indivior?

During the past quarter, Daniel A. Ninivaggi has bought $27,427.25 in shares of Indivior stock. Most recently, on Monday, January 5th, Daniel A. Ninivaggi bought 775 shares of Indivior stock. The stock was acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director now directly owns 16,923 shares of the company's stock, valued at $598,904.97. Learn More on Daniel A. Ninivaggi's trading history.

Who are Indivior's active insiders?

Indivior's insider roster includes Keith Humphreys (Director), Daniel Ninivaggi (Director), Barbara Ryan (Director), Mark Stejbach (Director), and David Wheadon (Director). Learn More on Indivior's active insiders.

Are insiders buying or selling shares of Indivior?

In the last twelve months, Indivior insiders bought shares 5 times. They purchased a total of 4,871 shares worth more than $172,384.69. The most recent insider tranaction occured on January, 5th when Director Barbara Ryan bought 775 shares worth more than $27,427.25. Learn More about insider trades at Indivior.

Information on this page was last updated on 1/5/2026.

Daniel A. Ninivaggi Insider Trading History at Indivior

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2026Buy775$35.39$27,427.2516,923View SEC Filing Icon  
See Full Table

Daniel A. Ninivaggi Buying and Selling Activity at Indivior

This chart shows Daniel A Ninivaggi's buying and selling at Indivior by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Indivior Company Overview

Indivior logo
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Read More

Today's Range

Now: $32.54
Low: $32.16
High: $33.10

50 Day Range

MA: $34.34
Low: $29.83
High: $36.60

2 Week Range

Now: $32.54
Low: $7.62
High: $38.00

Volume

2,317,098 shs

Average Volume

2,192,063 shs

Market Capitalization

$4.07 billion

P/E Ratio

35.37

Dividend Yield

N/A

Beta

0.75